Ropinirole hydrochloride CR is a Small Molecule owned by Hisamitsu Pharmaceutical Co, and is involved in 6 clinical trials, which were completed.
Ropinirole acts as dopamine receptors D3 and D2 agonist stimulate these receptors in the striatum. It alleviates the dopamine deficiency which characterizes Parkinson's disease by stimulating striatal dopamine receptors. Ropinirole influences striatal neuronal firing rates by activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
The revenue for Ropinirole hydrochloride CR is expected to reach a total of $967m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ropinirole hydrochloride CR NPV Report.
Ropinirole hydrochloride CR Overview
Ropinirole hydrochloride (Haruropi) is an indoline derivative, acts as an anti-Parkinson agent. It is formulated as controlled release tape for transdermal application. Ropinirole hydrochloride is indicated for the treatment of Parkinson's disease.
It was also under development for the treatment of idiopathic restless legs syndrome.
Kyowa Kirin Overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.
Quick View – Ropinirole hydrochloride CR
|Highest Development Stage|